Pharmacological treatment of cognitive deficits in schizophrenic patients: the effects of central cholinergic augmentation on cognitive deficits and psychopathology.
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2011
At a glance
- Drugs Donepezil; Ziprasidone
- Indications Schizophrenia
- Focus Therapeutic Use
- 19 Sep 2011 Planned end date (Jan 2005) added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Mar 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.